Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Breast Cancer
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Chemotherapy Resistance
100%
Poziotinib
100%
Multi-organ Metastases
100%
Tyrosine Kinase Inhibitor
60%
Neratinib
60%
Pan-HER
60%
HER2-mutant
60%
Metastatic Breast Cancer
40%
HER2 mutation
40%
Prognostic Significance
20%
Differential Effects
20%
Histology
20%
Metastasis
20%
Patient-derived Xenograft
20%
Tumor Growth
20%
Clinical Evaluation
20%
MCF-7
20%
Therapeutic Effect
20%
Endocrine Therapy
20%
Mammalian Target of Rapamycin (mTOR)
20%
Therapeutic Responsiveness
20%
Fulvestrant
20%
Chemotherapy Sensitivity
20%
Medicine and Dentistry
Breast Cancer
100%
Poziotinib
100%
Tyrosine-Kinase Inhibitor
60%
Neratinib
60%
Metastatic Breast Cancer
40%
Prevalence
20%
Clinical Trial
20%
Tumor Progression
20%
Xenograft
20%
Hormone Therapy
20%
Therapy Effect
20%
Mammalian Target of Rapamycin
20%
Fulvestrant
20%
Histology
20%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Poziotinib
100%
Protein Tyrosine Kinase Inhibitor
60%
Neratinib
60%
Metastatic Breast Cancer
40%
Clinical Trial
20%
Prevalence
20%
Tumor Growth
20%
Therapeutic Effect
20%
Endocrine Therapy
20%
Fulvestrant
20%
Biochemistry, Genetics and Molecular Biology
Tyrosine Kinase Inhibitor
100%
Neratinib
100%
Prevalence
33%
Clinical Trial
33%
Tumor Progression
33%
Mammalian Target of Rapamycin
33%
Fulvestrant
33%